ATE205403T1 - Zusammensetzungen welche aldosereductasehemmer und glycogen phosphorylase hemmer enthalten - Google Patents

Zusammensetzungen welche aldosereductasehemmer und glycogen phosphorylase hemmer enthalten

Info

Publication number
ATE205403T1
ATE205403T1 AT98949193T AT98949193T ATE205403T1 AT E205403 T1 ATE205403 T1 AT E205403T1 AT 98949193 T AT98949193 T AT 98949193T AT 98949193 T AT98949193 T AT 98949193T AT E205403 T1 ATE205403 T1 AT E205403T1
Authority
AT
Austria
Prior art keywords
inhibitors
compositions containing
aldose reductase
glycogen phosphorylase
containing aldose
Prior art date
Application number
AT98949193T
Other languages
English (en)
Inventor
Banavara Lakshman Mylari
Dennis Jay Hoover
Bernard Hulin
Judith Lee Treadway
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Application granted granted Critical
Publication of ATE205403T1 publication Critical patent/ATE205403T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Superheterodyne Receivers (AREA)
  • Noise Elimination (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
AT98949193T 1997-11-21 1998-11-02 Zusammensetzungen welche aldosereductasehemmer und glycogen phosphorylase hemmer enthalten ATE205403T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6636597P 1997-11-21 1997-11-21
PCT/IB1998/001752 WO1999026659A1 (en) 1997-11-21 1998-11-02 Combination of an aldose reductase inhibitor and a glycogen phosphorylase inhibitor

Publications (1)

Publication Number Publication Date
ATE205403T1 true ATE205403T1 (de) 2001-09-15

Family

ID=22069038

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98949193T ATE205403T1 (de) 1997-11-21 1998-11-02 Zusammensetzungen welche aldosereductasehemmer und glycogen phosphorylase hemmer enthalten

Country Status (38)

Country Link
EP (1) EP1032424B9 (de)
JP (1) JP2002504478A (de)
KR (2) KR20010032304A (de)
CN (1) CN1279617A (de)
AP (1) AP911A (de)
AR (1) AR016423A1 (de)
AT (1) ATE205403T1 (de)
AU (1) AU733304B2 (de)
BG (1) BG104435A (de)
BR (1) BR9814698A (de)
CA (1) CA2310069A1 (de)
DE (1) DE69801680T2 (de)
DK (1) DK1032424T3 (de)
DZ (1) DZ2656A1 (de)
EA (1) EA002365B1 (de)
ES (1) ES2161548T3 (de)
GR (1) GR3037071T3 (de)
GT (1) GT199800166A (de)
HR (1) HRP20000327A2 (de)
HU (1) HUP0100272A3 (de)
ID (1) ID24524A (de)
IL (1) IL135713A0 (de)
IS (1) IS5453A (de)
MA (1) MA26568A1 (de)
NO (1) NO20002164L (de)
OA (1) OA11379A (de)
PA (1) PA8462301A1 (de)
PE (1) PE135399A1 (de)
PL (1) PL340643A1 (de)
PT (1) PT1032424E (de)
SK (1) SK7222000A3 (de)
TN (1) TNSN98211A1 (de)
TR (1) TR200001451T2 (de)
UA (1) UA57811C2 (de)
UY (1) UY25258A1 (de)
WO (1) WO1999026659A1 (de)
YU (1) YU30700A (de)
ZA (1) ZA9810636B (de)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1150674A1 (de) * 1999-02-12 2001-11-07 Novo Nordisk A/S Verwendung von pyrrolidinderivaten zur herstellung von arzneizusammenstellungen zur behandlung oder prophylaxe von fettleibigkeit und appetitregulierung
ATE385421T1 (de) 2000-01-21 2008-02-15 Novartis Pharma Gmbh Zusammensetzungen bestehend aus dipeptidylpeptidase-iv inhibitoren und antidiabetica
CO5271699A1 (es) * 2000-01-24 2003-04-30 Pfizer Prod Inc Procedimiento para el tratamiento de cardiomiopatia utilizando inhibidores de la glucogeno fosforilasa
US6570013B2 (en) 2000-02-16 2003-05-27 Pfizer Inc Salts of zopolrestat
US6395767B2 (en) 2000-03-10 2002-05-28 Bristol-Myers Squibb Company Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
IL144507A0 (en) * 2000-07-31 2002-05-23 Pfizer Prod Inc Use of glycogen phosphorylase inhibitors to inhibit tumor growth
WO2002098429A1 (en) * 2001-06-07 2002-12-12 Pfizer Products Inc. Ethanolamine, diethanolamine or triethanolamine salt of zopolrestat
GB0205170D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205165D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205162D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205176D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205175D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205166D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
US7057046B2 (en) 2002-05-20 2006-06-06 Bristol-Myers Squibb Company Lactam glycogen phosphorylase inhibitors and method of use
CA2392486A1 (en) 2002-07-05 2002-12-08 Duchesnay Inc. Pharmaceutical dosage form bearing pregnancy-friendly indicia
US7098235B2 (en) 2002-11-14 2006-08-29 Bristol-Myers Squibb Co. Triglyceride and triglyceride-like prodrugs of glycogen phosphorylase inhibiting compounds
US7576121B2 (en) 2003-11-12 2009-08-18 Phenomix Corporation Pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
US7767828B2 (en) 2003-11-12 2010-08-03 Phenomix Corporation Methyl and ethyl substituted pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
US7317109B2 (en) 2003-11-12 2008-01-08 Phenomix Corporation Pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
AU2004288831B2 (en) 2003-11-12 2010-08-26 Phenomix Corporation Heterocyclic boronic acid compounds
WO2006017292A1 (en) 2004-07-12 2006-02-16 Phenomix Corporation Constrained cyano compounds
US7223786B2 (en) 2004-11-15 2007-05-29 Bristol-Myers Squibb Company 2-aminonaphthalene derivatives and related glycogen phosphorylase inhibitors
US7214704B2 (en) 2004-11-15 2007-05-08 Bristol-Myers Squibb Company 2-Amino-1-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors
US7226942B2 (en) 2004-11-15 2007-06-05 Bristol-Myers Squibb Company 2-amino-4-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors
US7365061B2 (en) 2004-11-15 2008-04-29 Bristol-Myers Squibb Company 2-Amino-3-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors
EP1879881A2 (de) 2005-04-14 2008-01-23 Bristol-Myers Squibb Company Inhibitoren der 11-beta-hydroxysteroiddehydrogenase vom typ i
US7825139B2 (en) 2005-05-25 2010-11-02 Forest Laboratories Holdings Limited (BM) Compounds and methods for selective inhibition of dipeptidyl peptidase-IV
GEP20135791B (en) 2005-09-14 2013-03-25 Takeda Pharmaceutical Use of dipeptidyl peptidase inhibitors
US8318941B2 (en) 2006-07-06 2012-11-27 Bristol-Myers Squibb Company Pyridone/hydroxypyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors
US7727978B2 (en) 2006-08-24 2010-06-01 Bristol-Myers Squibb Company Cyclic 11-beta hydroxysteroid dehydrogenase type I inhibitors
US8546394B2 (en) 2007-04-17 2013-10-01 Bristol-Myers Squibb Company Substituted [1,2,4]triazolo[4,3-A]pyrazine 11-beta-hydroxysteroid dehydrogenase inhibitors
PE20090222A1 (es) 2007-05-04 2009-03-27 Bristol Myers Squibb Co Compuestos [6,6] y [6,7]-biciclicos como agonistas del receptor acoplado a la proteina g gpr119
EP2152707B1 (de) 2007-05-04 2012-06-20 Bristol-Myers Squibb Company An gpr119-g-protein gekoppelte [6,5]-bicyclische rezeptoragonisten
PL2170864T3 (pl) 2007-07-17 2012-02-29 Bristol Myers Squibb Co Agoniści receptora gpr119 sprężonego z białkiem g - pirydon
TW201006821A (en) 2008-07-16 2010-02-16 Bristol Myers Squibb Co Pyridone and pyridazone analogues as GPR119 modulators
WO2011041293A1 (en) 2009-09-30 2011-04-07 Takeda Pharmaceutical Company Limited Pyrazolo [1, 5-a] pyrimidine derivatives as apoptosis signal-regulating kinase 1 inhibitors
SI2531501T1 (sl) 2010-02-03 2014-04-30 Takeda Pharmaceutical Company Limited Inhibitorji kinaze-1, ki regulirajo signal apoptoze
US8415367B2 (en) 2010-04-08 2013-04-09 Bristol-Myers Squibb Company Pyrimidinylpiperidinyloxypyridinone analogues as GPR119 modulators
EP2558461B1 (de) 2010-04-14 2015-12-02 Bristol-Myers Squibb Company Neuartige glucokinase-aktivatoren und verfahren zu ihrer verwendung
EP2566862B1 (de) 2010-05-06 2015-09-16 Bristol-Myers Squibb Company Benzofuranyl-analoga als gpr119-modulatoren
CN102971311B (zh) 2010-05-06 2015-07-08 百时美施贵宝公司 作为gpr119调节剂的二环杂芳基化合物
RS54447B1 (sr) 2011-01-20 2016-06-30 Bionevia Pharmaceuticals Inc. Modifikovano oslobađajuće kompozicije epalrestata ili njegovih derivata i postupci njihove upotrebe
US9174965B2 (en) 2012-05-16 2015-11-03 Bristol-Myers Squibb Company Pyrimidinylpiperidinyloxypyridone analogues as GPR119 modulators
WO2015061272A1 (en) 2013-10-22 2015-04-30 Bristol-Myers Squibb Company Isotopically labeled triazolopyridine 11-beta hydroxysteroid dehydrogenase type i inhibitors
CN109715637B (zh) 2016-07-22 2022-04-05 百时美施贵宝公司 葡萄糖激酶激活剂及其使用方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4825448A (en) * 1986-08-07 1989-04-25 International Mobile Machines Corporation Subscriber unit for wireless digital telephone system
DE3889326D1 (de) * 1988-05-27 1994-06-01 Itt Ind Gmbh Deutsche Korrekturschaltung für ein digitales Quadratur-Signalpaar.
US5391551A (en) * 1993-05-10 1995-02-21 Pfizer Inc. Method of lowering blood lipid levels
MX9709875A (es) * 1995-06-06 1998-03-31 Pfizer N-(indol-2-carbonil)-glicinamidas substituidas y derivados como inhibidores de glicogeno fosforilasa, composiciones que las contienen y uso de las mismas.
US6297269B1 (en) * 1995-06-06 2001-10-02 Pfizer Inc. Substituted n-(indole-2-carbonyl-) amides and derivatives as glycogen phosphorylase inhibitors

Also Published As

Publication number Publication date
HUP0100272A3 (en) 2002-11-28
MA26568A1 (fr) 2004-12-20
KR100661214B1 (ko) 2006-12-26
PA8462301A1 (es) 2000-05-24
ZA9810636B (en) 2000-05-22
IL135713A0 (en) 2001-05-20
TNSN98211A1 (fr) 2005-03-15
AR016423A1 (es) 2001-07-04
NO20002164L (no) 2000-07-19
DZ2656A1 (fr) 2003-03-22
PT1032424E (pt) 2001-12-28
GR3037071T3 (en) 2002-01-31
EP1032424B9 (de) 2004-10-06
AP9801401A0 (en) 1998-12-31
UY25258A1 (es) 2000-12-29
DE69801680D1 (de) 2001-10-18
OA11379A (en) 2004-01-28
EP1032424A1 (de) 2000-09-06
KR20010032304A (ko) 2001-04-16
DE69801680T2 (de) 2002-02-07
ID24524A (id) 2000-07-20
WO1999026659A1 (en) 1999-06-03
UA57811C2 (uk) 2003-07-15
NO20002164D0 (no) 2000-04-27
BG104435A (bg) 2001-01-31
JP2002504478A (ja) 2002-02-12
CN1279617A (zh) 2001-01-10
ES2161548T3 (es) 2001-12-01
SK7222000A3 (en) 2001-09-11
EP1032424B1 (de) 2001-09-12
BR9814698A (pt) 2000-10-03
PL340643A1 (en) 2001-02-12
CA2310069A1 (en) 1999-06-03
YU30700A (sh) 2002-12-10
HUP0100272A2 (hu) 2001-06-28
AP911A (en) 2000-12-07
AU9555898A (en) 1999-06-15
AU733304B2 (en) 2001-05-10
PE135399A1 (es) 2000-01-15
GT199800166A (es) 2000-04-19
DK1032424T3 (da) 2001-11-19
EA200000433A1 (ru) 2000-12-25
IS5453A (is) 2000-04-14
EA002365B1 (ru) 2002-04-25
HRP20000327A2 (en) 2001-02-28
KR20010032300A (ko) 2001-04-16
TR200001451T2 (tr) 2002-06-21

Similar Documents

Publication Publication Date Title
DE69801680D1 (de) Zusammensetzungen welche aldosereductasehemmer und glycogen phosphorylase hemmer enthalten
ATE251892T1 (de) Schäumende öl-zusammensetzung und ihre verwendung
DE69637691D1 (de) Azeotropähnliche zusammensetzungen und ihre verwendung
DE69638056D1 (de) Azeotropähnliche zusammensetzungen und ihre verwendung
HUP0103575A2 (hu) Kaszpáz inhibitorok peptidek, azokat hatóanyagként tartalmazó gyógyszerkészítmények és alkalmazásuk
DE69932552D1 (de) Pulver-Zusammensetzung und kosmetische Zusammensetzung enthaltend dieselbe
DE60025147D1 (de) Kosmetische Zusammensetzung und Verwendungen
DE60014599D1 (de) Zusammensetzungen aus difluormethan, pentafluorethan, 1,1,1,2-tetrafluorethan und kohlenwasserstoffen
DE59913617D1 (de) Indolderivate und deren Verwendung als Inhibitoren der Phosphodiesterase 4.
DE69840599D1 (de) Antimikrobielle chinolone, ihre zusammensetzungen und ihre verwendungen
DE69823804D1 (de) Azeotrope methoxyperfluorpropanzusammensetzungen und deren verwendung
DE69826662D1 (de) 4-brom or 4-iod-phenylamino-benzhydroxamsäurederivate und ihre anwendung als mek-inhibitoren
NO20011950D0 (no) Farmasöytisk sammensetning inneholdende poly(ADP- ribose)glykohydrolaseinhibitorer og anvendelser av de samme
DE69926681D1 (de) Verbrennungskammer und deren Arbeitsweise
DE69915066D1 (de) Biozide zusammensetzung und deren verwendung
DE69513307D1 (de) Zusammensetzung und verwendung
PL338004A1 (en) Derivatives of azetidinylpropylpiperidine, intermediate compounds and application of such derivatives as antagonists of tachykinins
HUP0102646A3 (en) Phthalazine derivatives phosphodiesterase 4 inhibitors and pharmaceutical compositions containing the same
GB9827391D0 (en) Aldose reductase inhibitors and pharmaceutical compositions
DE69800435D1 (de) Feste kosmetische Zusammensetzung sowie ihre Verwendungen
ATE274024T1 (de) Sauerstoffabsorbierende zusammensetzung und ihre anwendungsmethode
DE69900414D1 (de) Verzögerungssysteme und verwendung in ölbohrlochzementierungen
ID26297A (id) Celana jenis celana pendek sekali pakai dan proses pembuatannya
DE69828864D1 (de) Pigmentzusammensetzung und damit hergestellte wässrige Pigmentdispersion
FI962327A0 (fi) Kaasumaisten päästöjen vähentäminen hakesiilosta

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee